Topoisomerase levels determine chemotherapy response in vitro and in vivo
- 1 July 2008
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 105 (26), 9053-9058
- https://doi.org/10.1073/pnas.0803513105
Abstract
Topoisomerase poisons are chemotherapeutic agents that are used extensively for treating human malignancies. These drugs can be highly effective, yet tumors are frequently refractory to treatment or become resistant upon tumor relapse. Using a pool-based RNAi screening approach and a well characterized mouse model of lymphoma, we explored the genetic basis for heterogeneous responses to topoisomerase poisons in vitro and in vivo. These experiments identified Top2A expression levels as major determinants of response to the topoisomerase 2 poison doxorubicin and showed that suppression of Top2A produces resistance to doxorubicin in vitro and in vivo. Analogously, using a targeted RNAi approach, we demonstrated that suppression of Top1 produces resistance to the topoisomerase 1 poison camptothecin yet hypersensitizes cancer cells to doxorubicin. Importantly, lymphomas relapsing after treatment display spontaneous changes in topoisomerase levels as predicted by in vitro gene knockdown studies. These results highlight the utility of pooled shRNA screens for identifying genetic determinants of chemotherapy response and suggest strategies for improving the effectiveness of topoisomerase poisons in the clinic.Keywords
This publication has 42 references indexed in Scilit:
- A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast CancerCancer Cell, 2007
- Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancerProceedings of the National Academy of Sciences of the United States of America, 2007
- Synthetic lethal screen identification of chemosensitizer loci in cancer cellsNature, 2007
- Probing tumor phenotypes using stable and regulated synthetic microRNA precursorsNature Genetics, 2005
- Second-generation shRNA libraries covering the mouse and human genomesNature Genetics, 2005
- Prognostic significance of del(20q) in patients with hematological malignanciesCancer Genetics and Cytogenetics, 2005
- An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivoNature Genetics, 2003
- RNA interferenceNature, 2002
- Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage‐induced S and G2 checkpoints and enhances apoptotic activity in HEK‐293 cellsFEBS Letters, 2001
- Mutations of Human Topoisomerase IIα Affecting Multidrug Resistance and SensitivityBiochemistry, 1999